@article {486, title = {UP1304, a Botanical Composition Containing Two Standardized Extracts of Curcuma longa and Morus alba, Mitigates Pain and Inflammation in Adjuvant-induced Arthritic Rats}, journal = {Pharmacognosy Research}, volume = {8}, year = {2016}, month = {February 2016}, pages = {112-117}, type = {Original Article}, chapter = {112}, abstract = {

Background: Though, the initial etiologies of arthritis are multifactorial, clinically, patients share pain as the prime complaints. Present day pain relief therapeutics heavily relies on the use of prescription and over the counter nonsteroidal anti-inflammatory drugs as the first line of defense where their long-term usage causes gastrointestinal and cardiovascular-related side effects. Hence, the need for evidence-based safer and efficacious alternatives from natural sources to overcome the most prominent and disabling symptoms of arthritis is an overdue. Here, we evaluated the anti-inflammatory and analgesic effect of UP1304, a composition that contains a standardized blend of two extracts from the rhizome of Curcuma longa and the root bark of Morus alba in adjuvant-induced arthritis models in rats. Materials and Methods: The anti-inflammatory and analgesic effects of the botanical composition were demonstrated in adjuvant-induced arthritis models in rats with oral dose ranges of 50{\textendash}200 mg/kg. Ibuprofen at a dose of 100 mg/kg was used as a reference compound. Ex vivo sulfated glycosaminoglycan inhibition assays were performed. Results: Statistically significant improvements in pain resistance, suppression of paw edema and ankle thickness were observed in animals treated with UP1304 compared to vehicle-treated diseased rats. These results were similar to those achieved by ibuprofen treatment. Inhibitions of proteoglycan degradation were observed in a range of 37.5{\textendash}61.7\% for concentration of UP1304 at 50{\textendash}200 {\textmu}g/mL when compared to interleukin-1α-exposed untreated explants. Conclusions: These data suggest that UP1304, for its analgesic and anti-inflammatory effects, could potentially be considered agent of botanical origin for the improvement of arthritis associated symptoms.

}, keywords = {Anti-inflammatory, Arthritis, Bradykinin inhibition, Chronic pain, Curcuma longa, Morus alba}, doi = {10.4103/0974-8490.172563}, author = {Mesfin Yimam and Young-Chul Lee and Breanna Moore and Ping Jiao and Mei Hong and Jeong-Bum Nam and Mi-Ran Kim and Tae-Woo Kim and Hyun-Jin Kim and Eu-Jin Hyun and Min Chu and Lidia Brownell and Qi Jia} } @article {569, title = {Analgesic and Anti-Inflammatory Effect of UP3005, A Botanical Composition Containing Two Standardized Extracts of Uncaria gambir and Morus alba}, journal = {Pharmacognosy Research}, volume = {7}, year = {2015}, month = {June 2015}, pages = {s39-s46}, type = {Original Article}, chapter = {s39}, abstract = {

Background: Osteoarthritis (OA) is a chronic debilitating degenerative joint disease characterized by cartilage degradation and synovial inflammation exhibited by clinical symptoms such as joint swelling, synovitis, and inflammatory pain. Present day pain relief therapeutics heavily relies on the use of prescription and over the counter nonsteroidal anti-inflammatory drugs as the first line of defense where their long-term usage causes detrimental gastrointestinal and cardiovascular-related side-effects. As a result, the need for evidence based safer and efficacious alternatives from natural sources to overcome the most prominent and disabling symptoms of arthritis is a necessity. Materials and Methods: Describe the anti-inflammatory and analgesic effect of UP3005, a composition that contains a standardized blend of two extracts from the leaf of Uncaria gambir and the root bark of Morus alba in carrageenan-induced rat paw edema, abdominal constriction (writhing{\textquoteright}s) and ear swelling assays in mouse with oral dose ranges of 100-400 mg/kg. Results: In vivo, statistically significant improvement in pain resistance, and suppression of paw edema and ear thickness in animals treated with UP3005 were observed compared with vehicle-treated diseased rats and mice. Ibuprofen was used a reference compound in all the studies. In vitro, enzymatic inhibition activities of UP3005 were determined with IC50 values of 12.4 μg/ml, 39.8 μg/ml and 13.6 μg/ml in cyclooxygenase-2 (COX-1), COX-2 and lipoxygenase (5-LOX) enzyme activity assay, respectively. Conclusions: These data suggest that UP3005, analgesic and anti-inflammatory agent of botanical origin with balanced dual COX-LOX inhibition activity, could potentially be used for symptom management of OA.

}, keywords = {Chronic pain, Cyclooxygenase-lipoxygenase dual inhibitor, Morus alba, osteoarthritis, Uncaria gambir}, doi = { 10.4103/0974-8490.157995}, author = {Mesfin Yimam and Young-Chul Lee and Tae-Woo Kim and Breanna Moore and Ping Jiao and Mei Hong and Hyun-Jin Kim and Jeong-Bum Nam and Mi-Ran Kim and Jin-Sun Oh and Sabrina Cleveland and Eu-Jin Hyun and Min Chu and Qi Jia} }